Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fight for Biosite continues as Beckman ups bid to challenge IMI (Inverness Medical Innovations) head to head:

This article was originally published in Clinica

Executive Summary

Beckman Coulter this week opened the scene for an all-out bidding war after raising its bid for diagnostics developer Biosite to match the offer of its rival Inverness Medical Innovations (IMI). Beckman and Biosite had entered a merger agreement on March 24, in which the former would buy all outstanding Biosite stock in a cash tender offer for $85 per share. Days later IMI had come in with a higher offer of $90 per share, which Biosite said it will consider. As Beckman's cash tender offer was set to expire last week, there had been no indication from any of the players as to how the story would end. However, Fullerton, California-based Beckman has now upped its bid for Biosite to the same price with which IMI had hoped to entice the latter. As Clinica went to press, neither Biosite or IMI were available for comment.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel